Erasmus MC

Running trials

• Not yet recruiting

  Hepatic arterial infusion versus intravenous oxaliplatin in a safety, feasibility, and pharmacokinetic study of liver-dominant malignancies – ARTEMIS OXYS-I trial

  2026-527509-39-01· Phase 1/2· Source

• Recruiting

  Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer

  NCT07645625· Phase 4· Source

• Recruiting

  CBCT Guided Markerless SBRT for Renal Cell Cancer

  NCT07402109· Source

• Recruiting

  Clinical Impact of Using IMPROVE to Select Patients for Carotid Revascularisation

  NCT07556887· Source

• Not yet recruiting

  Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

  NCT07368985· Phase 2· Source

• Recruiting

  Higher Radiation Dose to the Tumor May Help Avoid Surgery in Rectal Cancer Patients

  NCT07616297· Source

• Recruiting

  A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack

  NCT07301034· Phase 3· Source

• Enrolling by invitation

  Multivitamin Impact on Micronutrient Status in GLP-1 Users: A Randomized Trial

  NCT07234916· Source

• Active, not recruiting

  Durability of Pulmonary Vein Isolation Using a Variable-Loop Biphasic Pulsed Field Ablation Catheter in Patients With Paroxysmal Atrial Fibrillation

  NCT07236619· Source

• Recruiting

  Accuracy and Sustainability of SCALE-EYE Evaluation for Measuring Reliable Polyp Size

  NCT07005453· Source

• Recruiting

  Prospective Data Collection Initiative on Thoracic Malignancies

  NCT06996249· Source

• Recruiting

  Smart Measurement of Circulating Tumor DNA

  NCT06989814· Source

• Recruiting

  Towards Cure Via Only Ultra-short ICB in CSCC

  NCT06823479· Phase 2· Source

• Recruiting

  Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

  NCT06921785· Phase 3· Source

• Active, not recruiting

  Thermotherapy for Locally Advanced Head and Neck Cancer

  NCT06761937· Phase 1· Source

• Recruiting

  PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis

  NCT06855329· Source

• Recruiting

  Omitting Therapeutic Lymph Node Dissection in Patients With Melanoma (Stage 3) and Major Pathological Response in the Index Lymph Node

  NCT06754904· Source

• Recruiting

  Diuretic Testing in Chronic Kidney Disease

  NCT06841692· Source

• Recruiting

  Evaluation of a Personalised Survivorship Care Plan App for Patients With Melanoma

  NCT06643286· Source

• Recruiting

  A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

  NCT06644781· Phase 3· Source

• Not yet recruiting

  Evaluation of Gixam's Efficacy Predicting Pre-cancerous Colorectal Polyps and Colorectal Cancer

  NCT06688110· Source

• Recruiting

  Glioblastoma Imaging for the Detection of Tumor Progression Using APTw-CEST MRI

  NCT07121842· Source

• Recruiting

  Urinary Tubular Biomarkers for Chronic Kidney Disease

  NCT06732349· Source

• Recruiting

  Detection of Aneuploidy in Cell Free DNA to Improve the Sensitivity of Diagnostic Peritoneal Lavage in Gastric Cancer

  NCT06308510· Source

• Recruiting

  The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma

  NCT06355427· Phase 2/3· Source

• Recruiting

  Esophageal Self-expandable Metal Stent for Malignant Strictures: a Safety and Efficacy Study

  NCT06364553· Source

• Active, not recruiting

  Mobile Screening for Major Depressive Disorder in Adults From an Ethnically and Socioeconomically Diverse Population.

  NCT05989412· Source

• Recruiting

  Spinal Cord Monitoring in Multiple Sclerosis

  NCT06827834· Source

• Active, not recruiting

  HOPE at Heart (HOPE) of Donor Hearts After Circulatory Death (DCD) Using the XVIVO Heart Assist Transport System.

  NCT06485596· Source

• Not yet recruiting

  FET-PET-Guided Management of Pseudoprogression in Glioblastoma

  NCT06480721· Source

• Recruiting

  Stereotactic Body Radiation Therapy After Chemotherapy for Unresectable Perihilar Cholangiocarcinoma

  NCT06493734· Source

• Active, not recruiting

  Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma

  NCT06183489· Phase 2· Source

• Recruiting

  To Quantify the Impact of Addition of the GAAD Score to Imaging in Patients with Chronic Liver Disease Eligible for HCC Surveillance.

  NCT06601231· Source

• Recruiting

  Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic Castration-sensitive Prostate Cancer

  NCT07260435· Phase 3· Source

• Recruiting

  Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics

  NCT06260410· Source

• Active, not recruiting

  RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy.

  NCT05883631· Source

• Enrolling by invitation

  Primary Percutaneous Stenting Above the Ampulla Versus Endoscopic Drainage for Unresectable Malignant Hilar Biliary Obstruction

  NCT06671418· Phase 3· Source

• Recruiting

  Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors

  NCT06301945· Source

• Active, not recruiting

  Neuroinflammation in FTLD

  NCT06870838· Source

• Recruiting

  Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients

  NCT05701241· Phase 4· Source

• Recruiting

  Dutch Registry of Pediatric Cardiac Arrest

  NCT06938009· Source

• Active, not recruiting

  Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)

  NCT05817942· Source

• Recruiting

  Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

  NCT04954599· Phase 1/2· Source

• Active, not recruiting

  Treatment of Exertional Heatstroke witH icE wAter Soaked Towels

  NCT05717777· Source

• Recruiting

  Prediction Models for Complications After CRT in Esophageal Cancer

  NCT06366828· Source

• Recruiting

  Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial

  NCT05652673· Source

• Recruiting

  National PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC)

  NCT05326620· Source

• Not yet recruiting

  Biopsy Versus Resection in Elderly Glioblastoma Patients. A Prospective Cohort Study.

  NCT05641220· Source

• Recruiting

  The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)

  NCT06283927· Source

• Recruiting

  Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer

  NCT05600127· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Liver and biliary tract cancer7 recruiting
• Childhood cancers6 recruiting
• Colorectal cancer6 recruiting
• Glioblastoma5 recruiting
• Gastric and esophageal cancer4 recruiting
• Lung cancer3 recruiting
• Melanoma3 recruiting
• Prostate cancer3 recruiting
• Cervical cancer2 recruiting
• Chronic kidney disease2 recruiting
• Head and neck cancer2 recruiting
• Kidney cancer2 recruiting
• Mesothelioma2 recruiting
• Neuroendocrine tumours2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Bladder cancer1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Coronary artery disease1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Follicular lymphoma1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Mantle cell lymphoma1 recruiting
• Multiple sclerosis1 recruiting
• Obesity1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Stroke1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Withdrawn

  INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701

  NCT05703555· Phase 2· Source

• Completed

  The Effectiveness of Adding Braun Anastomosis to Standard Child Reconstruction After Pancreatoduodenectomy

  NCT05709197· Source

• Completed

  Safety and Tolerability of AC01 in patients with heart failure

  2022-500347-20-00· Phase 1/2· Source

• Completed

  AF-FLOW Registry to Evaluate Electrographic Flow Mapping in Patients Undergoing Ablation for Atrial Fibrillation

  NCT05481359· Source

• Completed

  Feasibility, Reliability, and Satisfaction of CEA Using Home Based (Automated) Capillary Blood Sampling

  NCT05646030· Source

• Completed

  Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma

  NCT05449366· Phase 1/2· Source

• Completed

  A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL

  NCT04984356· Phase 1· Source

• Completed

  A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors

  NCT05053139· Phase 3· Source

• Terminated

  iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study

  NCT05416086· Source

• Completed

  PCT-guided Treatment Regarding Antibiotic Use for Acute COPD Exacerbations

  NCT05854901· Source

• Completed

  The Effects of an Nutritional Intervention on PD-1 ICI in NSCLC

  NCT05902260· Source

• Completed

  Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)

  NCT04880434· Phase 2· Source

• Completed

  Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

  NCT04644237· Phase 2· Source

• Completed

  Periprocedural Continuation Versus Interruption of Oral Anticoagulant Drugs During Transcatheter Aortic Valve Implantation (POPular PAUSE TAVI)

  NCT04437303· Phase 4· Source

• Completed

  Reduced Anticoagulation Targets in ECLS (RATE)

  NCT04536272· Phase 3· Source

• Completed

  Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis

  NCT04340076· Phase 4· Source

• Completed

  A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

  NCT04256421· Phase 3· Source

• Terminated

  IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study

  NCT03705403· Phase 2· Source

• Completed

  Long Term Extension Trial of Setmelanotide

  NCT03651765· Phase 2/3· Source

• Completed

  Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)

  NCT03112174· Phase 3· Source

• Completed

  Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex

  NCT03180736· Phase 3· Source

• Completed

  Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

  NCT02973789· Phase 3· Source

• Completed

  Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

  NCT02576496· Phase 1· Source

• Completed

  A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)

  NCT02614066· Phase 1/2· Source

• Completed

  New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement

  NCT02329080· Phase 2· Source

• Completed

  Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases

  NCT02162563· Phase 3· Source

• Completed

  Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

  NCT01909453· Phase 3· Source

• Completed

  Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer

  NCT01658930· Source